Form 10-Q Revance Therapeutics, For: Jun 30
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 8/20/2026
- US stock futures steady after tech slump; investors focus on Middle East tensions
- U.S. Treasury doubles buyback operation size for long-dated bonds
- Marvell shares jump after giving Google warrants amid custom chip deal
- U.S. debt tops $40 trillion
- Nvidia credit risk gauge hits new peak as SoftBank readies record bond issue
- Marvell issues Google warrant tied to custom chip deal
- FOMC minutes from July 28-29th meeting
- Lowe's Cos. (LOW) Tops Q2 EPS by 17c, Misses on Revenue; Offers Fy27 Guidance
- US stock futures steady after tech slump; investors focus on Middle East tensions
- Marvell shares jump after giving Google warrants amid custom chip deal
William Blair Downgrades Revance Therapeutic (RVNC) to Market Perform
August 12, 2024 11:12 AM EDTWilliam Blair analyst Tim Lugo downgraded Revance Therapeutic (NASDAQ: RVNC) from Outperform to Market Perform.
The analyst comments "Before the market open on Monday, August 12, Revance announced Crown Laboratories, a privately held, global leader in the skincare industry, will commence and... More
Stifel Downgrades Revance Therapeutic (RVNC) to Hold Following Go Private Deal
August 12, 2024 10:07 AM EDTStifel analyst Annabel Samimy downgraded Revance Therapeutic (NASDAQ: RVNC) from Buy to Hold with a price target of $6.66 (from $20.00).
The analyst comments "Surprising to us, RVNC announced this morning its intention to merge with Crown Laboratories, a privately-held, global skincare company for... More
